Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Vaxcyte ( (PCVX) ) has shared an update.
On February 24, 2026, Vaxcyte, Inc. entered into a new sales agreement with Leerink Partners LLC that allows the company to sell up to $500 million of its common stock from time to time in an at-the-market offering under an existing shelf registration. The arrangement provides flexible access to equity capital via sales on Nasdaq or other markets, with Leerink earning up to 3% of gross proceeds, while Vaxcyte retains discretion over whether, when and how many shares to sell, though there is no assurance any shares will be issued.
Effective the same date, Vaxcyte terminated its prior open market sale agreement with Jefferies LLC, under which it had already raised approximately $270.3 million since 2021, signaling a shift in placement partners but a continued reliance on at-the-market offerings as a key financing tool. The new facility could materially affect the company’s capital structure and funding capacity, with potential implications for existing shareholders depending on the scale and timing of future issuances.
The most recent analyst rating on (PCVX) stock is a Buy with a $85.00 price target. To see the full list of analyst forecasts on Vaxcyte stock, see the PCVX Stock Forecast page.
Spark’s Take on PCVX Stock
According to Spark, TipRanks’ AI Analyst, PCVX is a Neutral.
The score is held down primarily by weak financial performance (no revenue, accelerating losses and cash burn). Offsetting factors include a strong balance sheet bolstered by a large equity raise and supportive technical momentum with the stock trading above key moving averages.
To see Spark’s full report on PCVX stock, click here.
More about Vaxcyte
Vaxcyte, Inc. is a biotechnology company, as indicated by its use of equity capital markets and SEC shelf registration processes to fund operations and development. The company’s common stock is listed on the Nasdaq Global Select Market, and it has previously used “at-the-market” equity programs to raise capital for its business activities and growth initiatives.
Average Trading Volume: 1,410,354
Technical Sentiment Signal: Buy
Current Market Cap: $7.97B
Find detailed analytics on PCVX stock on TipRanks’ Stock Analysis page.